122 Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent ß-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3

Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Weijian Liu, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson

1 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion.

Suradej Hongeng, Alexis A. Thompson, Janet L. Kwiatkowski, Franco Locatelli, John B. Porter, John Rasko, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Andreas E. Kulozik, Evangelia Yannaki, Manfred Schmidt, Ying Chen, Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters